364 related articles for article (PubMed ID: 33814009)
1. Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin.
Cheng Y; Mo F; Li Q; Han X; Shi H; Chen S; Wei Y; Wei X
Mol Cancer; 2021 Apr; 20(1):62. PubMed ID: 33814009
[TBL] [Abstract][Full Text] [Related]
2. Feiyanning downregulating CXCLs/CXCR2 axis to suppress TANs infiltration in the prevention of lung cancer metastasis.
Wu X; Xia J; Wang Z; Xu Z; Liu K; Fu X; Deng H
J Ethnopharmacol; 2022 Sep; 295():115277. PubMed ID: 35427725
[TBL] [Abstract][Full Text] [Related]
3. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.
Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J
Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.
Tazzyman S; Barry ST; Ashton S; Wood P; Blakey D; Lewis CE; Murdoch C
Int J Cancer; 2011 Aug; 129(4):847-58. PubMed ID: 21328342
[TBL] [Abstract][Full Text] [Related]
5. The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer.
Ji HZ; Liu B; Ren M; Li S; Zheng JF; Liu TY; Yu HH; Sun Y
Expert Rev Clin Immunol; 2024 May; 20(5):559-569. PubMed ID: 38224014
[TBL] [Abstract][Full Text] [Related]
6. Targeting both tumour-associated CXCR2
Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CXCR2 plays a pivotal role in re-sensitizing ovarian cancer to cisplatin treatment.
Henriques TB; Dos Santos DZ; Dos Santos Guimarães I; Tessarollo NG; Lyra-Junior PCM; Mesquita P; Pádua D; Amaral AL; Cavadas B; Pereira L; Silva IV; Almeida RMDSG; Rangel LBA
Aging (Albany NY); 2021 May; 13(10):13405-13420. PubMed ID: 34038868
[TBL] [Abstract][Full Text] [Related]
8. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma.
Chao T; Furth EE; Vonderheide RH
Cancer Immunol Res; 2016 Nov; 4(11):968-982. PubMed ID: 27737879
[TBL] [Abstract][Full Text] [Related]
9. CXCR2-CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma.
Li L; Xu L; Yan J; Zhen ZJ; Ji Y; Liu CQ; Lau WY; Zheng L; Xu J
J Exp Clin Cancer Res; 2015 Oct; 34():129. PubMed ID: 26503598
[TBL] [Abstract][Full Text] [Related]
10. Deletion of C-C Motif Chemokine Ligand 5 Worsens Invariant Natural Killer T-Cell-Mediated Hepatitis via Compensatory Up-regulation of CXCR2-Related Chemokine Activity.
Chen L; Gu J; Qian Y; Li M; Qian Y; Xu M; Li J; Wen Y; Xia L; Li J; Xia Q; Kong X; Wu H
Cell Mol Gastroenterol Hepatol; 2019; 7(3):623-639. PubMed ID: 30630119
[TBL] [Abstract][Full Text] [Related]
11. Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1/8-CXCR2 Axis.
Ogawa R; Yamamoto T; Hirai H; Hanada K; Kiyasu Y; Nishikawa G; Mizuno R; Inamoto S; Itatani Y; Sakai Y; Kawada K
Clin Cancer Res; 2019 May; 25(9):2887-2899. PubMed ID: 30705034
[TBL] [Abstract][Full Text] [Related]
12. IL-17-CXC Chemokine Receptor 2 Axis Facilitates Breast Cancer Progression by Up-Regulating Neutrophil Recruitment.
Wu L; Awaji M; Saxena S; Varney ML; Sharma B; Singh RK
Am J Pathol; 2020 Jan; 190(1):222-233. PubMed ID: 31654638
[TBL] [Abstract][Full Text] [Related]
13. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.
Saintigny P; Massarelli E; Lin S; Ahn YH; Chen Y; Goswami S; Erez B; O'Reilly MS; Liu D; Lee JJ; Zhang L; Ping Y; Behrens C; Solis Soto LM; Heymach JV; Kim ES; Herbst RS; Lippman SM; Wistuba II; Hong WK; Kurie JM; Koo JS
Cancer Res; 2013 Jan; 73(2):571-82. PubMed ID: 23204236
[TBL] [Abstract][Full Text] [Related]
14. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.
Yang G; Rosen DG; Liu G; Yang F; Guo X; Xiao X; Xue F; Mercado-Uribe I; Huang J; Lin SH; Mills GB; Liu J
Clin Cancer Res; 2010 Aug; 16(15):3875-86. PubMed ID: 20505188
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.
Urbantat RM; Jelgersma C; Brandenburg S; Nieminen-Kelhä M; Kremenetskaia I; Zollfrank J; Mueller S; Rubarth K; Koch A; Vajkoczy P; Acker G
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681839
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
17. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
[TBL] [Abstract][Full Text] [Related]
18. Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis.
Sharma B; Nawandar DM; Nannuru KC; Varney ML; Singh RK
Mol Cancer Ther; 2013 May; 12(5):799-808. PubMed ID: 23468530
[TBL] [Abstract][Full Text] [Related]
19. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
[TBL] [Abstract][Full Text] [Related]
20. [Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes].
Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jun; 37(6):416-20. PubMed ID: 25200040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
